Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen

• US 8,158,609 B1
• Filed: 11/02/2007
• Issued: 04/17/2012
• Est. Priority Date: 11/02/2006
• Status: Expired due to Fees

• Current Assignee: Novartis Ag
• Original Assignee: Novartis Ag
• Inventors: Marsh, David Allen, Collier, Robert J. Jr., Kapin, Michael A., Tian, Youqin, Slovin, Eliot Mark
• Primary Examiner(s): Jiang, Shaojia Anna
• Assistant Examiner(s): Krishnan, Ganapathy
• Application Number:
  US11/934,132
• Time in Patent Office: 1,628 Days
• Field of Search: 514/58
• US Class Current: 514/58
• CPC Class Codes: A61K 31/724 Cyclodextrins
• CPC Class Codes: A61K 47/40 Cyclodextrins; Derivatives thereof
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears

Abstract

The present invention is directed to the treatment of disorders involving the accumulation of drusen, such as dry age-related macular degeneration and geographic atrophy via administration of therapeutically effective amounts of at least one monomeric or polymeric cyclodextrin.

Claims

1. A method for shrinking the size of drusen in the eye of a patient suffering from dry age-related macular degeneration by solubilizing the lipid component of said drusen, said method comprising administering to a patient in need thereof, a composition comprising from 20% to 80% by weight of at least one cyclodextrin selected from the group consisting of hydroxypropyl β

-cyclodextrin, sulfonyletherbutyl β

-cyclodextrin, and a polymer of β

-cyclodextrin, wherein the composition is administered via intravitreal injection, and wherein the lipid component of said drusen is solubilized within the cyclodextrin thereby shrinking the size of said drusen.

2. The method of claim 1, wherein the amount of cyclodextrin in the composition is from 20% to 50% by weight.

3. The method of claim 1, wherein the concentration of cyclodextrin in the composition is from about 40 μ

M to about 100 μ

M.

4. A method for solubilizing the lipid component of drusen in the eye of a patient suffering from dry age-related macular degeneration, said method comprising administering to said patient, a composition comprising from 20% to 80% by weight of at least one cyclodextrin selected from the group consisting of hydroxypropyl β

-cyclodextrin, sulfonyletherbutyl β

-cyclodextrin, and a polymer of β

-cyclodextrin, wherein the composition is administered via intravitreal injection.